ICPT
Price:
$19
Market Cap:
$794.69M
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United State...[Read more]
Industry
Biotechnology
IPO Date
2012-10-11
Stock Exchange
NASDAQ
Ticker
ICPT
According to Intercept Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -17.43. This represents a change of -30.35% compared to the average of -25.03 of the last 4 quarters.
The mean historical PE Ratio of Intercept Pharmaceuticals, Inc. over the last ten years is -7.76. The current -17.43 PE Ratio has changed 22.38% with respect to the historical average. Over the past ten years (40 quarters), ICPT's PE Ratio was at its highest in in the June 2014 quarter at 37.06. The PE Ratio was at its lowest in in the September 2023 quarter at -69.43.
Average
-7.76
Median
-7.88
Minimum
-18.16
Maximum
3.63
Discovering the peaks and valleys of Intercept Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 268.37%
Maximum Annual PE Ratio = 3.63
Minimum Annual Increase = -201.51%
Minimum Annual PE Ratio = -18.16
Year | PE Ratio | Change |
---|---|---|
2022 | 3.63 | -201.51% |
2021 | -3.58 | 42.48% |
2020 | -2.51 | -74.96% |
2019 | -10.03 | 8.12% |
2018 | -9.28 | 128.41% |
2017 | -4.06 | -37.43% |
2016 | -6.49 | -58.47% |
2015 | -15.63 | 36.52% |
2014 | -11.45 | -36.96% |
2013 | -18.16 | 268.37% |
The current PE Ratio of Intercept Pharmaceuticals, Inc. (ICPT) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-0.82
5-year avg
-4.35
10-year avg
-7.76
Intercept Pharmaceuticals, Inc.’s PE Ratio is greater than Viking Therapeutics, Inc. (-71.47), less than Terns Pharmaceuticals, Inc. (-6.12), less than Akero Therapeutics, Inc. (-9.66), greater than Reata Pharmaceuticals, Inc. (-89.36), less than Madrigal Pharmaceuticals, Inc. (-8.84), less than TG Therapeutics, Inc. (33.12), less than Hepion Pharmaceuticals, Inc. (-0.13), less than PTC Therapeutics, Inc. (-6.39), less than Krystal Biotech, Inc. (46.43), less than AVROBIO, Inc. (2.07), less than CohBar, Inc. (-0.12), less than Ocean Biomedical, Inc. (-0.92), less than Enveric Biosciences, Inc. (-0.30), less than Elevation Oncology, Inc. (-0.77), less than Sarepta Therapeutics, Inc. (236.04), less than Mirati Therapeutics, Inc. (-5.32),
Company | PE Ratio | Market cap |
---|---|---|
-71.47 | $6.94B | |
-6.12 | $665.36M | |
-9.66 | $1.98B | |
-89.36 | $6.57B | |
-8.84 | $4.58B | |
33.12 | $3.39B | |
-0.13 | $3.62M | |
-6.39 | $3.07B | |
46.43 | $4.94B | |
2.07 | $5.24M | |
-0.12 | $1.42M | |
-0.92 | $32.37M | |
-0.30 | $3.73M | |
-0.77 | $30.56M | |
236.04 | $11.25B | |
-5.32 | $4.12B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Intercept Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Intercept Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Intercept Pharmaceuticals, Inc.'s PE Ratio?
How is the PE Ratio calculated for Intercept Pharmaceuticals, Inc. (ICPT)?
What is the highest PE Ratio for Intercept Pharmaceuticals, Inc. (ICPT)?
What is the 3-year average PE Ratio for Intercept Pharmaceuticals, Inc. (ICPT)?
What is the 5-year average PE Ratio for Intercept Pharmaceuticals, Inc. (ICPT)?
How does the current PE Ratio for Intercept Pharmaceuticals, Inc. (ICPT) compare to its historical average?